(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual revenue growth rate of 17.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Protalix Biotherapeutics's revenue in 2026 is $61,840,000.On average, 3 Wall Street analysts forecast PLX's revenue for 2026 to be $5,833,028,679, with the lowest PLX revenue forecast at $5,079,643,056, and the highest PLX revenue forecast at $6,685,573,619.
In 2027, PLX is forecast to generate $5,906,131,533 in revenue, with the lowest revenue forecast at $5,730,732,937 and the highest revenue forecast at $6,140,076,748.